AI Article Synopsis
- The gastrointestinal tract cancer development occurs through a series of gradual changes that lead to advanced cancer stages.
- Recent advancements in technologies like next-generation sequencing and proteomics have improved our understanding of the molecular changes in precancerous lesions, though gaps in knowledge still exist.
- Future efforts should focus on identifying specific molecular markers related to disease progression, which can enhance clinical testing and prevention strategies for gastrointestinal cancers.
Article Abstract
The mainstream carcinogenic processes involved within the gastrointestinal tract are characterized by phenotypic multistep progression cascades that eventually result in full-blown cancers. In this scenario, the understanding of the molecular dysregulations underlying the precancerous lesions is increasing but still remains incomplete. However, in recent years, the enthusiastic rise of innovative technologies (i.e., next-generation sequencing, high-throughput microarray analysis, mass spectrometry based proteomics) and the unexpected discovery of new classes of biomarkers (i.e., miRNA, long-noncoding RNAs) prompted new strength in the exploration of the accurate and comprehensive molecular characterization of premalignant and malignant neoplastic lesions. The challenge ahead lies in the reliable identification of disease progression-specific targets to enable molecular testing in the clinical management of the secondary prevention of gastrointestinal cancers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bpg.2013.03.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!